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Abstract 
 
Objective: To evaluate the relationship between topically applied non-steroidal anti-
inflammatory drugs and upper gastro-intestinal bleeding and perforation. 
 
Study population: The population of 319,465 people who were resident in Tayside and 
were registered with a Tayside GP between January 1989 and October 1994. A record-
linkage database containing all hospital event and dispensed drug data between 1989 
and 1992 was used for this population. 
 
Design: A case-control study with 1,103 cases who were hospitalised for upper gastro-
intestinal bleeding or perforation between January 1990 and December 1992. Two 
different control groups were used, with six community controls and with two hospital 
controls for each case. Prior exposure to topical NSAIDs, oral NSAIDs and ulcer 
healing drugs was assessed. 
 
Main outcome measures: Unadjusted and adjusted odds ratios of exposure in 
hospitalised cases compared with controls. 
 
Results: Significant unadjusted associations were detected between all three classes of 
drug and upper gastro-intestinal complications. The significant association detected for 
topical NSAIDs was no longer evident in analyses which adjusted for the confounding 
effect of concomitant exposure to oral NSAIDs and ulcer healing drugs (OR = 1.45, 
0.84-2.50 using community controls; OR = 1.06, 0.60-1.88 using hospital controls).   
 
Conclusion: In this study, topical NSAIDs were not significantly associated with upper 
gastro-intestinal bleeding and perforation, after adjusting for the confounding effects of 
concomitant oral NSAIDs and ulcer healing drugs. 
 
 
Introduction 
 
 It is known that the use of oral non-steroidal anti-inflammatory drugs (NSAIDs) is 
associated with upper gastro-intestinal complications, particularly perforated and bleeding 
peptic ulcer
1
. Meta-analyses suggest that the relative risk is approximately three
2
. Recent 
studies have shown this risk to be dose-related
3,4
. This is one reason why the use of topically 
applied NSAIDs (topical NSAIDs) is advocated, as plasma concentrations of the NSAIDs 
remain relatively low after topical application. Despite this, spontaneous reporting data from 
the “Yellow Card” system of the Medicines Control Agency5 suggest that the risks of topical 
NSAIDs may not be negligible. For example, since July 1963, there have been seven reports 
of adverse events in the gastro-intestinal tract following topical application of diclofenac, 
four with ibuprofen, one with ketoprofen, 25 with piroxicam and 47 with felbinac (an active 
metabolite of fenbufen)
6
. 
 
 Furthermore, in a post marketing study of 23,590 patients exposed to topical Felbinac 
3% gel (Traxam, Lederle Pharmaceuticals), 327 patients experienced 331 adverse events of 
which 24 were related to the gastrointestinal tract
7
. This study may have been confounded by 
the use of other drugs as 17 of these patients were taking additional medication. Nevertheless, 
six were judged to be “definitely” or “probably” related to topical NSAID use.  
 
 In order to clarify the risks associated with topically applied NSAIDs, we have carried 
out a case-control study with multiple control groups  using a record-linkage database 
containing data for a population of 319,465 people, purpose built for carrying out such 
pharmacoepidemiological research. 
Methods 
 
 The study was carried out using the Medicines Monitoring Unit’s record-linkage 
database at the University of Dundee. This database contains prospectively gathered 
information on all dispensed community prescriptions for NSAIDs and ulcer-healing drugs in 
Tayside from January 1 1989, and diagnostic and demographic data on all hospitalised 
patients in Tayside from 1980 (Scottish Morbidity Record 1). These data can be linked by a 
unique ten-digit number, the Community Health Number. The data collection methods for 
this database have been described in detail elsewhere
8
. In brief, prescriptions encashed at 
Tayside pharmacies were sent to the Medicines Monitoring Unit following dispensing. The 
patient’s name, address and other prescription details were used to find the unique 
Community Health Number using purpose-written software to search the Community Health 
Index for Tayside. This is a list of all patients registered with a General Practitioner which is 
maintained by Tayside Health Board. Dispensed prescribing details were entered onto the 
prescription database with the Community Health Number. 
 
 When patients in Tayside are discharged from hospital, codes for their diagnoses 
(International Classification of Disease version 9) and codes for their operations (Office of 
Population Censuses and Surveys, fourth revision) are entered onto the Tayside section of the 
Scottish Morbidity Record database, using the Community Health Number as an identifier. 
Copies of these data are held within the Medicines Monitoring Unit.  
 
 The Community Health Number allows the temporal linking of dispensed prescription 
data and hospitalisation data. In addition, since the Medicines Monitoring Unit has lists of 
every patient registered with a General Practitioner in Tayside and every person hospitalised 
in Tayside, both community and hospital controls can be generated. 
 
SAMPLE SIZE CALCULATION 
 
 In a preliminary analysis, the extent of topical NSAID prescribing and the 
preparations most commonly prescribed were investigated for the population of Tayside 
between 1989 and 1992. Using this information, the minimum odds ratios which could be 
detected with the sample sizes used in the case-control study were calculated. 
 
STUDY POPULATION 
 
 The study population comprised 319,465 people who were resident in Tayside and 
were registered with a Tayside General Practitioner in January 1989 and were either still 
resident in October 1994, or had died in Tayside during this period. 
 
CASES 
 
 A case was defined as any individual within the study population who had an 
International Classification of Disease code for upper gastrointestinal bleeding or perforation 
in their computerised discharge summary for a hospitalisation episode between January 1 
1990 and December 31 1992. The codes used were for acute, chronic or unspecified gastric 
ulcer, duodenal ulcer or gastrojejunal ulcer, with haemorrhage, with haemorrhage and 
perforation, or with perforation. Codes for haematemesis and melaena were also used. (A full 
list of codes is available from the Journal on request). The first hospitalization with such an 
episode was taken to be the case episode. 
 
VALIDATION OF CASE IDENTIFICATION 
 
 A validation study was carried out to estimate the sensitivity and specificity of the 
computerised International Classification of Disease codes to identify cases in this study. 
Hospital episodes containing any gastro-intestinal code were identified for all patients over 
50 years of age who had cashed a prescription for an NSAID between 1989 and 1991. The 
original case records were then reviewed by seven medically qualified staff, and a further 
sample audited by two consultant physicians, one a Gastroenterologist (FEM). The separate 
events that the episodes represented were assessed and, using predetermined criteria, were 
judged to be acute bleeds or perforations, or otherwise. It was thus possible to determine how 
many “true cases” (ie acute bleeds and perforations) would be missed, and how many “non-
cases” would be incorrectly selected, if case identification was based on the International 
Classification of Disease codes alone. 
 
COMMUNITY CONTROLS 
 
 From the study population, up to six community controls, matched for sex and age 
(within 30 days), were generated randomly for each case. These controls were all still alive in 
September 1992. The index date of the case and its matched control was the date of the case’s 
first admission to hospital.  
 
HOSPITAL CONTROLS 
 
 Up to two hospital controls, matched for sex, age (within 365 days) and hospital of 
admission were generated randomly for each case. They could have been admitted to hospital 
with any diagnosis other than gastro-intestinal bleeding and perforation within 90 days of the 
case. The index date of the hospital control was the date of admission. 
 
ANALYSES 
 
 Prior exposure to three classes of drugs were investigated - oral NSAIDs (excluding 
aspirin), ulcer-healing drugs and topical NSAIDs. Odds ratios were calculated for two pre-
defined exposure variables for each, and modelled using conditional logistic regression
9,10
. 
These were: 
 
1. Forty five day exposure: One or more prescriptions dispensed during a 45 day 
 period prior to the index date. 
 
2. Ever exposure: One or more prescriptions dispensed at any time from January 1 
 1989 to the index date. 
 
 The more significant exposure variable for each drug was included in the final model. 
If neither variable was significant, or they were equally significant, ever exposure was 
modelled. Thus the results for each drug are given with the confounding effects of the other 
drugs removed. The analyses were also carried out for bleeding and perforation separately. 
 
 Results 
 
SAMPLE SIZE CALCULATION 
 
 The utilisation of topical NSAID preparations in the study population between 1989 
and 1992 is displayed in Table 1. The level of exposure during the time of the study was 7%. 
Since the study included 1,103 cases, the minimum odds ratio which could have been 
detected, at the 5% level of significance, with 80% power, and with six controls per case was 
1.4 (n = 1,081). With only two controls per case, the minimum odds ratio was 1.5 (n = 958)
11
. 
 
CASES AND VALIDATION OF CASES 
 
 There were 1,103 patients hospitalised for upper gastro-intestinal bleeding and 
perforation between January 1 1990 and December 31 1992. 569 (52%) were male and 534 
(48%) were female. 78% were over the age of 50 years. 
 
 The validation study examined 3,078 admission-discharge events that contained at 
least one upper gastro-intestinal diagnostic code, of which 542 were acute bleeding events 
and 75 were perforations. The sensitivity of using the diagnostic codes used for this study to 
identify cases was calculated to be 68% for acute bleeds and 79% for perforations. The 
specificity was 98%. 
 
CONTROLS 
 
 A total of 6,593 suitable community controls and 2,184 suitable hospital controls were 
found for these cases. No suitable community controls could be found for two cases which 
were therefore excluded from the relevant analyses. No suitable hospital controls could be 
found for seven cases which were also excluded.  
 
RESULTS OF CASE-CONTROL STUDIES 
 
 Using community controls, oral NSAIDs, topical NSAIDs and ulcer healing drugs 
were significantly associated with upper gastro-intestinal bleeding and perforation, whether 
45 day exposure or ever exposure variables were used (Table 2). With hospital controls, both 
the exposure variables were statistically significant for ulcer healing drugs but only 45 day 
exposure was significant for oral NSAIDs. Neither exposure variable was statistically 
significant for topical NSAIDs (Table 3). 
 
 The results of the conditional regression analyses which adjusted for the effects of 
exposure to the other drugs simultaneously, and also investigated the separate end-points of 
bleeding and perforation, are shown in Tables 4 and 5. The few cases which had both 
bleeding and perforation were excluded. Oral NSAIDs and ulcer healing drugs were 
significantly associated with an increased risk of gastro-intestinal complications in all cases. 
There were no significant associations between topical NSAIDs and gastro-intestinal events 
after adjusting for confounding by oral NSAIDs and ulcer healing drugs. 
 
 The effects of confounding were investigated in further conditional regression 
analyses. With community controls, topical NSAIDs were still associated with upper gastro-
intestinal complications after adjusting for oral NSAIDs alone, suggesting that there was 
further confounding from ulcer healing drugs. Similarly, there was confounding from ulcer 
healing drugs after adjusting for oral NSAIDs. However, with hospital controls, it was 
enough to adjust for just one class of drug to remove all the confounding effects. This was 
because most of the excess risk associated with topical NSAIDs among cases compared to 
hospital controls was among patients exposed to both oral NSAIDs and ulcer healing drugs 
simultaneously. However, the excess risk with community controls seemed to be more evenly 
distributed among patients on different combinations of these drugs. (The analyses and 
contingency tables for these effects are shown in Appendix 1. They are not intended for 
publication but we suggest that they be available from the Journal on request).  
 
 To investigate further the validity of the result for topical NSAIDs, the analyses were 
recalculated using a repeated random control selection technique. Ten further hospital and ten 
further community control groups were assembled and the analyses repeated for each. The 
adjusted results for 45 day exposure and ever exposure to topical NSAIDs are shown in Fig 1. 
(The individual components and the data for Fig 1 are enclosed to aid publication). 
Discussion 
 
 These results show that whilst there were associations between the use of topical 
NSAIDs and upper gastro-intestinal complications in the unadjusted analyses, these 
associations were mainly due to confounding by concomitant use of oral NSAIDs and ulcer 
healing drugs. In analyses which adjusted for the effects of all the three classes of drug 
simultaneously, there were no significant associations between topical NSAIDs and upper 
gastro-intestinal complications. 
 
 There was some disparity between the results obtained using the different control 
groups. Assessing the validity of different control groups is often a difficult problem in case-
control studies. However, irrespective of the source of controls, the final results were similar, 
in that topical NSAIDs did not carry an independent significant risk of gastro-intestinal 
complications.  
 
 One possible weakness of this study may relate to statistical power. The original 
power calculations were based on 7% exposure to topical NSAIDs. However, this was 
appropriate only for the ever exposure analyses. Based on 45 day exposure to topical 
NSAIDs, to which 2% of cases and controls were exposed, the minimum odds ratios which 
could have been detected were nearer 2
11
. An adjusted odds ratio of 1.45 was found for 45 
day exposure to topical NSAIDs using community controls. This was not significant, but this 
may have been due to lack of power. Indeed, the plot of 45 day exposure using community 
controls suggests that a very small risk associated with topical NSAID use might be present. 
This may not represent a true toxic effect but may be evident because patients already at high 
risk from upper gastro-intestinal complications are prescribed topical NSAIDs in an effort to 
avoid the toxicity of oral NSAIDs.   
 
 An independent estimated relative risk of 2.6 (2.1 - 3.2) was found for oral NSAIDs 
using community controls, and 2.0 (1.6 - 2.5) using hospital controls. These figures are 
consistent with previous research
2
. An independent increased risk associated with ulcer 
healing drugs was also found in this study. This is unlikely to be a causal association but 
probably arises because people known to be at high risk from gastro-intestinal bleeding and 
perforation, or have symptoms already, are prescribed ulcer-healing drugs. 
 
 The importance of misclassification and bias must be considered. 
 
MISCLASSIFICATION OF DISEASE STATUS 
 
 Concerns have been expressed as to the accuracy of International Classification of 
Disease codes which were used to identify cases in this study. For example, a review of 150 
case records for discharges from Medicine and Paediatrics in the Tayside region suggested 
that these diagnostic codes in Scottish Morbidity Record data were unacceptable in 21%
12
. 
Our case record validation showed that the sensitivity of identifying cases is indeed quite 
low, but that the specificity is higher, albeit in a particular group of patients. So although a 
proportion of the cases will have been missed, possibly even 30%, there will be few cases 
incorrectly identified. This is acceptable for a case-control study. 
 
EXPOSURE MISCLASSIFICATION 
 
 Misclassification of exposure is also a possible source of bias. Prescriptions were 
assigned to individuals by looking up their Community Health Number on computer from 
name and address details recorded on their prescriptions. A small proportion of Community 
Health Numbers could not be identified, while others may have been assigned wrongly. From 
internal quality control systems, the error rate of misclassification is known to be less than 
2%. In any case, such misclassification will be similar between cases and controls which 
would tend to mask any associations
13
. We do not think a significant exposure bias exists as 
the well described association between oral NSAIDs and gastro-intestinal bleeding and 
perforation is evident.  
 
SELECTION BIAS 
 
 Selection bias occurs if criteria for selecting subjects into a study are not consistent. 
The only difference in inclusion criteria between cases and community controls in this study 
was due to a computing technicality which meant that community controls were still alive in 
September 1992, whereas cases could have died after hospitalisation. This could mean that 
controls were healthier than cases and therefore less likely to be exposed to drugs. However, 
this bias would tend to increase the odds ratio, rather than mask a significant association. 
There were no differences in selection criteria between cases and hospital controls. This 
might explain some of the disparity between the results using the different control groups.  
 
 One of the strengths of the present study is that it did not rely on patient recall of 
exposure, thereby eliminating recall bias. We know that the prescriptions were dispensed, 
which is an important factor
14
, although we could not control for patients who were non-
compliant. 
  There are some limitations to the study design. No information was available on 
confounding factors such as smoking and alcohol. Past medical history of gastro-intestinal 
events was not controlled for. Also, the indications for the drugs were not known. Finally, the 
exposure periods of 45 days or ever exposure may not adequately explore the temporal 
relationship between exposure to topical NSAIDs and gastro-intestinal complications. The 
variables were chosen empirically and different exposure variables may yield different 
results. 
 
 With these limitations in mind, no statistically significant independent associations 
between topical NSAID use and hospitalisation for upper gastro-intestinal bleeding and 
perforation have been found. 
 
The Medicines Monitoring Unit is supported by the Medicines Control Agency. 
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LEGENDS TO TABLES 
 
 
Table 1: Utilisation of topical NSAIDs in study population 1989-1992 
 
Table 2: Crude odds ratios for exposure variables (community controls) 
 
Table 3: Crude odds ratios for exposure variables (hospital controls) 
 
Table 4: Final conditional logistic regression analyses (community controls) 
 
Table 5: Final conditional logistic regression analyses (hospital controls) 
 
   
Preparation No of prescriptions No of patients 
Diethylamine salicylate (Algesal, Duphar) 92 25 
Glycol salicylate (Algipan, Whitehall) 93 73 
Ammonium salicylate (Aspellin, Fisons) 53 30 
Methyl salicylate (Balmosa, Pharmax) 28 17 
Benzydamine hydrochloride (Difflam, 3M) 9,500 4,848 
Piroxicam (Feldene,Pfizer) 16,357 9,925 
Ibuprofen (Ibugel, Dermal) 432 330 
Ibuprofen (Ibuleve, Dendron) 54 41 
Salicylamide (Intralgin, 3M) 138 103 
Salicylic acid (Movelat, Panpharma) 1,869 1,089  
Ketoprofen (Oruvail, Rhone-Poulenc Rorer) 815 677 
Ibuprofen (Proflex, Zyma) 2,486 1,405 
Tetrahydrofurfuryl salicylate (Transvasin, 
Lederle) 
332 200 
Felbinac (Traxam, Lederle) 5,358 3,314 
Diclofenac (Voltarol, Geigy) 6,624 3,983 
Total 43,831 23,103 
1989 4,409 3,207 
1990 7,788 5,361 
1991 11,961 7,767 
1992 19,822 11,745 
 
Table 1 
  
 Cases 
(n = 1,101) 
Controls 
(n = 6,593) 
Unadjusted odds 
ratio (95% CI) 
p value 
Oral NSAIDs     
45 day exposure 186 (16.9%) 457  (6.9%) 2.81 (2.33, 3.40) <0.001 
Ever exposure 457 (41.5%) 2131 (32.3%) 1.53 (1.33, 1.75) <0.001 
Topical NSAIDs     
45 day exposure 23 (2.1%) 54  (0.8%) 2.59 (1.58, 4.23) <0.001 
Ever exposure  98 (8.9%) 415 (6.3%) 1.48 (1.17, 1.88) <0.001 
Ulcer-healing 
drugs 
    
45 day exposure 243 (22.1%) 393 (6.0%) 4.61 (3.85, 5.52) <0.001 
Ever exposure 421 (38.2%) 849 (12.9%) 4.33 (3.74, 5.01) <0.001 
 
Table 2 
 
  
 Cases 
(n = 1,096) 
Controls 
(n = 2,184) 
Unadjusted odds 
ratio (95% CI) 
p value 
Oral NSAIDs     
45 day exposure 186 (17.0%) 206 (9.4%) 1.98 (1.60, 2.46) <0.001 
Ever exposure 457 (41.7%) 909 (41.6%) 1.00 (0.86, 1.17) 0.970 
Topical NSAIDs     
45 day exposure 23  (2.1%) 29 (1.3%) 1.59 (0.92, 2.74) 0.099 
Ever exposure 97  (8.9%) 192 (8.8%) 1.00 (0.78, 1.30) 0.983 
Ulcer-healing 
drugs 
    
45 day exposure 242 (22.1%) 288 (13.2%) 1.88 (1.55, 2.28) <0.001 
Ever exposure 417 (38.0%) 569 (26.1%) 1.75 (1.50, 2.05) <0.001 
 
Table 3 
  
Exposure variable Adjusted odds ratio p value 
All cases   
45 day exposure - oral NSAIDs 2.59 (2.12, 3.16) <0.001 
45 day exposure - topical NSAIDs 1.45 (0.84, 2.50) 0.184 
Ever exposure - ulcer healing drugs 4.21 (3.63, 4.88) <0.001 
Bleeding   
45 day exposure - oral NSAIDs 2.18 (1.75, 2.71) <0.001 
Ever exposure - topical NSAIDs 1.43 (0.81, 2.54) 0.221 
Ever exposure - ulcer healing drugs 4.30 (3.67, 5.03) <0.001 
Perforation     
45 day exposure - oral NSAIDs 8.75 (4.77, 16.06) <0.001 
Ever exposure - topical NSAIDs 5.50 (0.70, 44.40) 0.106 
Ever exposure - ulcer healing drugs 3.51 (2.13,   5.79) <0.001 
 
Table 4 
  
Exposure variable Adjusted odds ratio p value 
All cases   
45 day exposure - oral NSAIDs 2.00 (1.60, 2.50) <0.001 
45 day exposure - topical NSAIDs 1.06 (0.60, 1.88) 0.851 
Ever exposure - ulcer healing drugs 1.76 (1.51, 2.07) <0.001 
Bleeding   
45 day exposure - oral NSAIDs 1.74 (1.37, 2.22) <0.001 
45 day exposure - topical NSAIDs 1.05 (0.57, 1.92) 0.875 
Ever exposure - ulcer healing drugs 1.74 (1.47, 2.05) <0.001 
Perforation    
45 day exposure - oral NSAIDs 4.84 (2.49, 9.39) <0.001 
45 day exposure - topical NSAIDs 0.86 (0.10, 7.28) 0.892 
Ever exposure - ulcer healing drugs 1.87 (1.07, 3.27) 0.028 
 
Table 5 
 
